I read with interest the paper by Henriksson et al, ' in which the authors demonstrated an altered character in the small bowel's bacterial flora in patients with rheumatoid arthritis. However, the authors did not demonstrate the presence of bacterial overgrowth. The syndrome of bacterial overgrowth is characterised by diarrhoea with malabsorption. The mechanism by which the bacterial overgrowth causes symptoms is not known. These symptoms are related to an increase in the luminal bacterial flora and the presence of obligate anaerobes (colonic luminal flora) as judged by jejunal fluid culture or breath tests. The patients in the study did not have any evidence of malabsorption or diarrhoea.
The investigations used, apart from the bile acid deconjugation test, had not been previously validated in patients with bacterial overgrowth. Quantative bacterial culture was not done; the bacterial flora was of oral type, not colonic. The presence of enterobacteriacae (a facultative anaerobe), tryptic activity, gas production (both not specific to obligate anaerobes) and the use of jejunal biopsy culture (biopsies culture produces different flora than fluid culture) are not proven features of bacterial overgrowth of the small bowel. The controls used did not have the syndrome of bacterial overgrowth as they were clinically well (achlorhydria, whilst associated with an altered and increased bacterial flora, does not We feel that the two concepts bacterial overgrowth and bacterial overgrowth syndrome are sometimes confused. We used the concept bacterial overgrowth to designate an altered microflora in the upper small intestine in patients with RA, and the criteria were clearly stated in the article. The bacterial overgrowth syndrome, also known as blind loop or stagnant loop syndrome, is characterised by steatorrhea and other signs of malabsorption. We agree that our patients with RA did not have the bacterial overgrowth syndrome.
Dr Lewis, however, seems to presume that only an altered small intestinal microflora complicated by the bacterial overgrowth syndrome is of interest in patients with RA. This view has to be questioned as we still do not know what types or quantities of microbes demonstrated in the upper small intestine are of interest in these patients.
The aim of our study was not to describe a bacterial overgrowth syndrome in patients with RA, but rather to denote an altered small intestinal microflora. A combination of techniques was preferred to get a comprehensive picture of small intestinal microflora, as it has been shown that different tests may be necessary to detect bacterial overgrowth in the upper small intestine.' It has been suggested that a qualitative change may be more important than a quantitative change;2 3 hence we used the growth of Enterobacteriaceae (Escherichia coli or KIebsiella) without counting the microorganisms as one of the criteria of bacterial overgrowth. These species originate from the colonic and not from the oral microflora.
The clinical significance of our findings is still uncertain. The RA patients with signs of bacterial overgrowth had significantly higher rheumatic disease activity as well as rheumatoid factor titre. Dr Lewis's suggestion that the changes in the small bowel bacterial flora may be secondary to multi-system involvement of RA certainly cannot be excluded. As for his contention that treatment with proton pump inhibitors or antibiotics would confirm our hypothesis, it should be noted that the small intestinal bacterial overgrowth in these patients was not only related to lack of gastric acid and that we know very little about the types of microorganisms involved; severe flare ups after treatment with antibiotics have been observed in patients with RA,4 possibly by changing the intestinal microflora in the 'wrong' direction. ' The occurrence of glomerulonephritis in RP seems to be even more frequent (29 of 112 patients). " These vasculitic symptoms may be attributed to an underlying PSV, that has not previously been recognised as such. We conclude that the occurrence ofANCA in RP should encourage thorough investigation for the presence of PSV, in which the polychondritis may be a secondary phenomenon. This is important, as the vasculitis determines the therapy and prognosis of the disease.
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9Matters an'si'ug Such discrepancies might result from recruitment bias and/or differences in the size of the studied groups, but also from the major problem of diagnostic procedures which requires further discussion.
Obviously, vascular involvement is frequent in RP and can affect vessels of any size, from aorta to capillaries. Its frequency has been said to be as high as 56% in McAdam's series.3 In RP, microscopic angiitis has proved to represent the anatomical basis responsible for dermatological and renal manifestations, and is suspected to cause neuropathies, audiovestibular disturbances and episcleritis. 3 4 RP is frequently associated with various inflammatory or autoimmune disorders, ranging from ulcerative colitis and rheumatoid arthritis, two ANCA-associated diseases,5 6 to thyroiditis, spondylarthropathies and primary systemic vasculitides, including Behcet's syndrome.`Some of these diseases are clearly distinct from RP but associated with, while others share, many manifestations with RP which results in obscure nosological considerations and difficult differential diagnosis. The main problem is trying to distinguish RP from WG,' since both diseases frequently have striking similarities, mainly saddle nose deformity and laryngotracheal involvement (although resulting from different processes), arthritis, episcleritis and skin vasculitis. Necrotising glomerulonephritis, otitis, sinusitis, nasal septal perforation and proptosis, which are more suggestive of WG, also occur 
